Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

3.325 +0.035 (+1.06%)
Streaming Delayed Price Updated: 10:03 AM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,278
Open 3.310
Bid (Size) 3.320 (16)
Ask (Size) 3.330 (12)
Prev. Close 3.290
Today's Range 3.310 - 3.365
52wk Range 2.630 - 4.725
Shares Outstanding 99,161,234
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire

Performance

YTD
+1.1%
+1.1%
1 Month
-5.0%
-5.0%
3 Month
-3.1%
-3.1%
6 Month
-17.9%
-17.9%
1 Year
+19.6%
+19.6%

More News

Read More
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Provides 2025 Corporate and Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
From Whitefort Capital Management, LP
Via Business Wire
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
From Arbutus Biopharma Corporation
Via GlobeNewswire
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Participate in Jefferies Global Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Present Imdusiran Data at EASL Congress 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire

Frequently Asked Questions

Is Arbutus Biopharma Corporation - Common Stock publicly traded?
Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
What is the current price of Arbutus Biopharma Corporation - Common Stock?
The current price of Arbutus Biopharma Corporation - Common Stock is 3.325
When was Arbutus Biopharma Corporation - Common Stock last traded?
The last trade of Arbutus Biopharma Corporation - Common Stock was at 04/28/25 10:03 AM ET
What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
The market capitalization of Arbutus Biopharma Corporation - Common Stock is 329.71M
How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
Arbutus Biopharma Corporation - Common Stock has 330M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.